Entyvio (Vedolizumab IV) Extended Access Program in Ulcerative Colitis and Crohn’s Disease

Takeda Development Centre Europe Limited0 sites385 target enrollmentMay 10, 2016

Overview

No summary available.

Registry

who.int

Start Date

May 10, 2016

End Date

TBD

Last Updated

5 years ago

Study Type

Interventional clinical trial of medicinal product

Sex

All

Sponsor

Takeda Development Centre Europe Limited

•Any subject who meets the inclusion criteria for the qualifying vedolizumab clinical studies and meets any of the following criteria will qualify for entry into the study:
•1\. Received vedolizumab (excluding comparator or placebo subjects) during participation in a qualifying vedolizumab study.
•2\. In the opinion of the investigator, the subject is continuing to derive benefit from vedolizumab and continued treatment with vedolizumab is desired because there is no other comparable product available or the subject may be expected to develop worsening of disease if they were to modify treatment.
•3\. A male subject who is nonsterilized and sexually active with a female partner of childbearing potential agrees to use adequate contraception from signing of informed consent throughout the duration of the study and for 18 weeks after last dose.
•4\. A female subject of childbearing potential who is sexually active with a nonsterilized male partner agrees to use routinely adequate contraception from signing of informed consent throughout the duration of the study and for 18 weeks after last dose.
•PK Substudy:
•5\. Received vedolizumab during participation in the C13008 protocol.
•6\. The subject will start the main XAP study on Q8W dosing.
•7\. The subject or, when applicable, the subject’s legally acceptable representative, has signed and dated a written ICF for the procedures related to the XAP\-PK substudy.
•Are the trial subjects under 18? no

•Any subject who meets any of the exclusion following criteria will not qualify for entry into the study:
•1\. For the subject’s particular clinical scenario, vedolizumab is currently available to the subject through commercial channels, including reimbursement.
•2\. Subject has any clinical condition or prior therapy that, in the opinion of the investigator, would make the subject unsuitable for the study or unable to comply with the dosing requirements or poses a risk to the subject being in the study.
•3\. If female, the subject is pregnant or lactating or intending to become pregnant before, during, or within 18 weeks after participating in this study; or intending to donate ova during such time period.
•4\. If male, the subject intends to donate sperm during the course of this study or for 18 weeks thereafter.
•5\. Subject has received a live vaccine in the last 18 weeks or is in need of a live vaccine during the study or up to 18 weeks after the last study dose.